drugset
Drugs / nOPV1
last change May 2026 re-read 3 minutes ago

nOPV1

also known as Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine · Novel Oral Polio Vaccine Type 1

Vaccine

Developed for
poliomyelitis
Investigated by
Bill and Melinda Gates Foundation · Centers for Disease Control and Prevention · PATH · PT Bio Farma · Centro de Vacunación e Investigación (Cevaxin) · DiagnoSearch Life Sciences Pvt. Ltd.
+1 more · Technical Resources International, Inc.

Trials 2

today NCT06895486 · Ph 2 NCT05644184 · Ph 2
2024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06895486 Nov 2025 → Dec 2026 expected poliomyelitis PATH Recruiting No outcome recorded
Phase 2 NCT05644184 Mar 2023 → May 2026 overdue poliomyelitis PATH Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as nOPV1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05644184 ↗
1

NCT06895486 ↗
Known as Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine “Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)” NCT05644184 ↗
Known as Novel Oral Polio Vaccine Type 1 “Novel Oral Polio Vaccine Type 1 (nOPV1)” NCT06895486 ↗
Modality Vaccine “novel oral polio type 1 vaccine” NCT05644184 ↗
Route Oral “Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)” NCT05644184 ↗